John Tan

1 week ago | ophthalmologytimes.com | Martin Harp |Hattie Hayes |John Tan

Author(s):,Researchers stratified a dataset of more than 100 patients in an emergency department to see which patients may be indicated for retinal artery occlusions. The Association for Research in Vision and Ophthalmology (ARVO) is hosting its annual meeting in Salt Lake City, Utah this year. At the ARVO meeting, researchers' posters and podium presentations cover a wide range of ocular pathologies, diagnostic technologies, and practice modalities.

2 weeks ago | mondaq.com | Andrew Chen |John Tan |Alex Wang |Siyi Gu

AP Arnold & Porter More Arnold & Porter is a firm of more than 1,000 lawyers, providing sophisticated litigation and transactional capabilities, renowned regulatory experience and market-leading multidisciplinary practices in the life sciences and financial services industries. Our global reach, experience and deep knowledge allow us to work across geographic, cultural, technological and ideological borders.

2 weeks ago | arnoldporter.com | Andrew Chen |John Tan |Alex Wang |Siyi Gu

On March 19, 2025, China’s National Medical Products Administration (NMPA) released the Draft Implementing Measures and Working Procedures for Drug Clinical Trial Data Protection (the Draft Measures) for public comment, due by May 18, 2025.1 The Draft Measures, together with China’s regulatory schemes for patent linkage and market exclusivity, are a significant development in China’s regulatory data exclusivity protection and demonstrate Chinese regulators’ commitment to aligning with...

Jan 29, 2025 | mondaq.com | Andrew Chen |John Tan |Alex Wang |Siyi Gu

The life sciences industry remained a primary focus for Chineseregulators in 2024. Key developments such as China's firstdraft law regulating the medical device industry, the MedicalDevice Administration Law(《中华人民共和国医疗器械管理法（草案征求意见稿）》),and the Compliance Guidelines for Healthcare Companies to PreventCommercial Bribery Risks(《医药企业防范商业贿赂风险合规指引》),marked milestones in the development of China's regulatoryframework for the industry.

Jan 24, 2025 | arnoldporter.com | Andrew Chen |John Tan |Alex Wang |Siyi Gu

The life sciences industry remained a primary focus for Chinese regulators in 2024. Key developments such as China’s first draft law regulating the medical device industry, the Medical Device Administration Law (《中华人民共和国医疗器械管理法（草案征求意见稿）》), and the Compliance Guidelines for Healthcare Companies to Prevent Commercial Bribery Risks (《医药企业防范商业贿赂风险合规指引》) marked milestones in the development of China’s regulatory framework for the industry.